Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Keytruda in HIV-infected patients with relapsed/refractory or disseminated malignant neoplasms
NCT02595866Phase 1Completed
- Sponsor
- National Cancer Institute
- Start
- Apr 2016
- Primary completion
- Oct 2023
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label trial of pembrolizumab in AIDS-related non-Hodgkin lymphoma (ARL), melanoma, hepatocellular carcinoma (HCC) and 4 more, sponsored by National Cancer Institute. Started Apr 2016; status: completed.
02
Drugs
03
Conditions
AIDS-related non-Hodgkin lymphoma (ARL)melanomahepatocellular carcinoma (HCC)Kaposi sarcoma (KS)non-small cell lung carcinoma (NSCLC)
Beyond the preview
Go deeper on NCT02595866.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02595866.